News Issued: Nov 4, 2024 (4:30pm EST) To view this online and get more information about Novavax Investor Relations visit: NOVAVAX TO HOST CONFERENCE CALL TO DISCUSS THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS ON NOVEMBER 12, 2024 GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows: Conference call details: Date: November 12, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events * Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back. * Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call. * To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. Replay details: Date: Available starting at 11:30 a.m. ET, November 12, 2024, until 11:59 p.m. U.S. ET, November 19, 2024 Dial-in number: (888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International) Passcode: 62491 # Webcast: ir.novavax.com/events, until December 12, 2024 About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts: Investors Luis Sanay, CFA 240-268-2022 [email protected] Media Giovanna Chandler 202-709-5563 [email protected] Novavax Logo (PRNewsfoto/Novavax) SOURCE Novavax, Inc.